Neurotech International Ltd. ( (AU:NTI) ) has shared an update.
Neurotech International Ltd has retracted a statement from its recent presentation at the NWR Virtual Healthcare Conference regarding its ‘Market Opportunity’ claims. The company acknowledged it lacked a reasonable basis for the statement and advised investors not to rely on it for making investment decisions. This retraction may impact investor confidence and the company’s market positioning.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused on pediatric neurological disorders. It specializes in a broad-spectrum oral cannabinoid drug therapy called NTI164 and has conducted various clinical trials, including those for Autism Spectrum Disorder and other pediatric neuropsychiatric conditions.
YTD Price Performance: -41.67%
Average Trading Volume: 705,048
Technical Sentiment Signal: Buy
Current Market Cap: A$36.47M
See more data about NTI stock on TipRanks’ Stock Analysis page.